Pancreatic Cancer


A New Standard of Care of Treatment for Resectable Pancreatic Cancer? (06-6-2016)

According to experts at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting the European Study Group for Pancreatic Cancer (ESPAC)-4 has presented results that will change the management of pancreatic cancer. Pancreatic cancer is one... Continue Reading

Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk (05-25-2016)

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing and genetic counseling service, today announced its... Continue Reading

Vistogard® Approved for Life-Threatening Toxicities of Certain Chemotherapy Agents (02-11-2016)

The United States Food and Drug Administration (FDA) approved Vistogard (uridine triacetate) for the treatment of life-threatening toxicities caused by the chemotherapy drugs fluorouracil or capecitabine. The approved indication is for the “emergency... Continue Reading

Onivyde Approved for Pancreatic Cancer (11-3-2015)

The United States Food and Drug Administration (FDA) approved Onivyde (irinotecan liposome injection) to be used in combination with fluorouracil and leucovorin for patients with advanced pancreatic cancer. The approval is indicated for patients with... Continue Reading

Protein Circulating in Blood Could Be Key to Early Diagnosis of Pancreatic Cancer (08-6-2015)

Research suggests a promising new way to screen for and detect early pancreatic cancer. Certain proteins that circulate in the blood may help identify patients with this disease, for which there’s currently no reliable screening. These findings were... Continue Reading

“Boosted” Radiation Dose May Make Some Pancreatic Cancers Resectable (06-24-2015)

Because of its location, cancers on the pancreas may invade and wrap around nearby veins and arteries in the abdomen. When these vessels become involved, surgery to remove the cancer, which is typically the standard treatment, becomes significantly more... Continue Reading

MM-398 Receives Fast Track Designation for Advanced Pancreatic Cancer (11-26-2014)

The U. S. Food and Drug Administration (FDA) has granted MM- 398 plus 5-fluorouracil (5-FU) and leucovorin a Fast Track designation as a second-line treatment for patients with metastatic pancreatic cancer, based on data from the phase III NAPOLI-1 study... Continue Reading

FDA Grants Orphan Drug Designation to Investigational Agent for Pancreatic Cancer (10-7-2014)

Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people are diagnosed with pancreatic cancer in the United States and close to 37,000 die from the disease. The disease is often diagnosed at an advanced stage,... Continue Reading

Simtuzumab Fails to Improve Outcomes in Pancreatic Cancer (09-23-2014)

Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people are diagnosed with pancreatic cancer in the United States and close to 37,000 die from the disease. The disease is often diagnosed at an advanced stage,... Continue Reading

In Advanced Pancreatic Cancer, Eloxatin® with Folinic Acid and Fluorouracil May Improve Survival (07-10-2014)

In a Phase III study, the addition of the chemotherapy drug Eloxatin® (oxaliplatin) to the chemotherapy regimen of folinic acid and fluorouracil (5-FU) improved outcomes in patients with advanced pancreatic cancer that had progressed on Gemzar® (gemcitabine).... Continue Reading

« Previous PageNext Page »